This clinical trial is focused on studying the progression of glaucoma, specifically open-angle glaucoma and PEX glaucoma. Glaucoma is a condition that affects the eyes and can lead to vision loss due to damage to the optic nerve. The study aims to compare two different treatment approaches for patients who have been newly diagnosed with this condition. The treatments being tested include a single medication approach and a combination of medications, which may include additional treatments like laser therapy. The medications involved in this study are brimonidine, pilocarpine nitrate, brinzolamide, timolol maleate, latanoprost, betaxolol, bimatoprost, dorzolamide hydrochloride, travoprost, and tafluprost. Some of these medications may be used in combination to enhance their effectiveness.
The purpose of the study is to observe and compare how quickly the disease progresses in patients receiving different types of treatment. Participants will be randomly assigned to either the intensive treatment group or the conventional treatment group. The study will monitor the rate of vision loss and any changes in the condition over time. This will help determine which treatment approach is more effective in slowing down the progression of glaucoma. The study will also consider the quality of life of the participants and how well they adhere to the treatment plan.
Participants in the study will receive treatment for a period of up to 120 days, with regular follow-ups to assess their condition. The study will continue to collect data on the participants’ eye health and vision changes. This information will be used to better understand the effectiveness of the treatments and to improve future care for individuals with glaucoma. The study is expected to conclude by the end of 2027.



Sweden